76 related articles for article (PubMed ID: 7745698)
1. RT-PCR detection of HIV in Republic of Macedonia.
Bosevska G; Panovski N; Dokić E; Grunevska V
Bosn J Basic Med Sci; 2008 Nov; 8(4):350-5. PubMed ID: 19125707
[TBL] [Abstract][Full Text] [Related]
2. WT
Francl M
Nat Chem; 2024 Jan; 16(1):1-2. PubMed ID: 38123843
[No Abstract] [Full Text] [Related]
3. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.
Sharma PL; Crumpacker CS
J Virol; 1999 Oct; 73(10):8448-56. PubMed ID: 10482597
[TBL] [Abstract][Full Text] [Related]
4. Managing resistance to anti-HIV drugs: an important consideration for effective disease management.
Vandamme AM; Van Laethem K; De Clercq E
Drugs; 1999 Mar; 57(3):337-61. PubMed ID: 10193687
[TBL] [Abstract][Full Text] [Related]
5. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.
Mulato AS; Lamy PD; Miller MD; Li WX; Anton KE; Hellmann NS; Cherrington JM
Antimicrob Agents Chemother; 1998 Jul; 42(7):1620-8. PubMed ID: 9660994
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains.
Srinivas RV; Fridland A
Antimicrob Agents Chemother; 1998 Jun; 42(6):1484-7. PubMed ID: 9624498
[TBL] [Abstract][Full Text] [Related]
7. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy.
Eastman PS; Mittler J; Kelso R; Gee C; Boyer E; Kolberg J; Urdea M; Leonard JM; Norbeck DW; Mo H; Markowitz M
J Virol; 1998 Jun; 72(6):5154-64. PubMed ID: 9573287
[TBL] [Abstract][Full Text] [Related]
8. Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR.
Dickover RE; Herman SA; Saddiq K; Wafer D; Dillon M; Bryson YJ
J Clin Microbiol; 1998 Apr; 36(4):1070-3. PubMed ID: 9542939
[TBL] [Abstract][Full Text] [Related]
9. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.
Sharma PL; Crumpacker CS
J Virol; 1997 Nov; 71(11):8846-51. PubMed ID: 9343245
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
Winters MA; Shafer RW; Jellinger RA; Mamtora G; Gingeras T; Merigan TC
Antimicrob Agents Chemother; 1997 Apr; 41(4):757-62. PubMed ID: 9087484
[TBL] [Abstract][Full Text] [Related]
11. Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment.
Zazzi M; Catucci M; De Milito A; Romano L; Venturi G; Almi P; Gonnelli A; Rubino M; Valensin PE
Infection; 1996; 24(6):419-25. PubMed ID: 9007588
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.
Clementi M; Menzo S; Bagnarelli P; Valenza A; Paolucci S; Sampaolesi R; Manzin A; Varaldo PE
Clin Microbiol Rev; 1996 Apr; 9(2):135-47. PubMed ID: 8964032
[No Abstract] [Full Text] [Related]
13. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo.
Bagnarelli P; Valenza A; Menzo S; Sampaolesi R; Varaldo PE; Butini L; Montroni M; Perno CF; Aquaro S; Mathez D; Leibowitch J; Balotta C; Clementi M
J Virol; 1996 Nov; 70(11):7603-13. PubMed ID: 8892880
[TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.
Davey RT; Chaitt DG; Reed GF; Freimuth WW; Herpin BR; Metcalf JA; Eastman PS; Falloon J; Kovacs JA; Polis MA; Walker RE; Masur H; Boyle J; Coleman S; Cox SR; Wathen L; Daenzer CL; Lane HC
Antimicrob Agents Chemother; 1996 Jul; 40(7):1657-64. PubMed ID: 8807058
[TBL] [Abstract][Full Text] [Related]
15. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.
Caliendo AM; Savara A; An D; DeVore K; Kaplan JC; D'Aquila RT
J Virol; 1996 Apr; 70(4):2146-53. PubMed ID: 8642636
[TBL] [Abstract][Full Text] [Related]
16. Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance.
Eastman PS; Boyer E; Mole L; Kolberg J; Urdea M; Holodniy M
J Clin Microbiol; 1995 Oct; 33(10):2777-80. PubMed ID: 8567926
[TBL] [Abstract][Full Text] [Related]
17. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.
Holodniy M; Mole L; Margolis D; Moss J; Dong H; Boyer E; Urdea M; Kolberg J; Eastman S
J Virol; 1995 Jun; 69(6):3510-6. PubMed ID: 7745698
[TBL] [Abstract][Full Text] [Related]
18. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
